Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: An add-on, double-blind placebo-controlled study

Israel Journal of Psychiatry and Related Sciences

Volumn 46, Issue 3, 2009, Pages 213-220

  Poyurovsky, Michael ^a,b   Faragian, Sarit ^a   Fuchs, Camil ^c   Pashinian, Artashez ^a  

^a Technion Medical School   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; BENZODIAZEPINE DERIVATIVE; MORPHOLINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; REBOXETINE;

ADULT; ARTICLE; COGNITIVE DEFECT; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOSIS; SCHIZOPHRENIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 75549086203     PISSN: 03337308     EISSN: 26172402     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2()()4;72: 41-51.
2. Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry 2006;67: ell.
3. Buchanan RVV, Freedman R, Javitt DC, Abi-Dargham A, Licberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairment in schizophrenia. Schizophr Bull 2007;33:1120-1130.
4. Gray JA, Roth BL. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 2007;33:1019-1100.
5. Arnsten AF. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berl) 2004; 174:25-31.
6. Arnsten AFT, Mathew R, Ubrani R, Taylor JR, Li BM. Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol Psychiatry 1999;160:12-16.
7. Arnsten AFT,Goldman-Rakic P. Alpha-2 adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 1985;230: 1273-1276.
8. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999;45,1-16.
9. Friedman JI, Adler DN, Temporini FID, Kemether E, Harvey PD, White L, Parrella M, Davis KL. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 2001;25: 402-409.
10. Friedman JI, Stewart DG, Gorman JM. Potential noradrenergic targets for cognitive enhancement in schizophrenia. CNS Spectr 2004;9: 350-355.
11. Gainetdinov RR, Sotnikova TD, Caron MG. Monoamine transporter pharmacology and mutant mice. Trends Pharmacol Sci 2002;23: 367-373.
12. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: Evidence from knock-out mouse lines. J Neurosci 2002; 22: 389-395.
13. Winterer G, Weinberger DR. Genes, dopamine and cortical signal-to-noise ratio in schizophrcnia.Trends Neurosci 2004;27: 83-690.
14. Stahl SM. Neurotransmission of cognition, part 1, Dopamine is a hitchhiker in frontal cortex: Norepinephrine transporters regulate dopamine. J Clin Psychiatry 2003;64: 4-5.
15. Siepmann M, Muck-Weymann M, Joraschky P, Kirch W. The effects of reboxetine on autonomic and cognitive functions in healthy volunteers. Psychopharmacology (Berl) 2001; 157:202-207.
16. Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: Effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol2Q03;18: 9-14.
17. Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Fara- gian S, Weizman R, Weizman A. Attenuation of olanzap- ine-induced weight gain with reboxetine in patients with schizophrenia: A double-blind, placebo-controlled study. Am J Psychiatry 2003;160: 297-302.
18. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Ma ay an R, Gil-Ad I. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: A double-blind placebo-controlled study. Psychopharmacology (Berl) 2007;192: 441-448.
19. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa, 1984.
20. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa, 1983.
21. Guy W. ECDE assessment manual for psychopharmacology. Revised DIIEW Pub (ADM), Rockville, Md.: National Institute of Mental Health, 1976.
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23: 56-62.
23. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676.
24. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212:11-19.
25. Reeves D, Kane R, Winter K. ANAM V3.11a/96 User's Manual: Clinical and Neurotoxicology Subsets. (Report No. NCRF-TR-96-01). San Diego, Cal.: National Cognitive Recovery Foundation. Neurotoxicology Subsets 1996.
26. Cohen J. A power primer. Psychol Bull 1992;112: 155-159.
27. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocogni- tive impairment in schizophrenia: A review and metaanalysis. Schizophr Bull 1999;25: 201-221.
28. Poyurovsky M, Koren D, Gonopolsky I, Schneidman M, Fuchs C, Weizman A, Weizman R. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: An add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol 2003;13: 123-128.
29. Geyer M.A, Heinssen R. New approaches to measurement and treatment research to improve cognition in schizophrenia. Schizophr Bull 2005;31: 806-809.
30. Rybakowski JK, Borkowska A, Czerski PM, Dmi- trzak-Weglarz M, Skibinska M, Kapelski P, Hauser J. Performance on the Wisconsin Card Sorting Test in schizophrenia and genes of dopaminergic inactiva- tion (COMT, DAT, NET). Psychiatry Res 2006;143: 13-19.
31. Szöke A, SchürhoffF, Méary A, Mathieu F, Chevalier F, Trandafir A, Alter C, Roy I, Bellivier F, Leboyer M. Lack of influence of COMT and NET genes variants on executive functions in schizophrenic and bipolar patients, their first-degree relatives and controls. Am J Med Genet B Neuropsychiatr Genet 2006;141: 504-512.
32. Friedman JI, Carpenter D, Lu J, Fan J, Tang CY, White L, Parrella M, Bowler S, Elbaz Z, Flanagan L, Harvey PD. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol 2008; 28:59-63.